FDA Approves BESREMi for Essential Thrombocythemia, the First New Therapy in About 30 Years

For roughly three decades, patients with essential thrombocythemia, a rare chronic blood cancer in which the bone marrow produces too many platelets, have had a thin menu of treatment options, most of them borrowed from other diseases or decades old. On Aug 31, the U.S. Food and Drug Administration approved BESREMi (ropeginterferon alfa-2b-njft) for adults with the condition, making it the first new FDA-approved treatment for essential thrombocythemia in about 30 years, as reported by BioPharm International on Aug 31 and confirmed by Fierce Pharma and CancerNetwork the same day. The approval extends a therapy that was already on the U.S. market for a related blood cancer, polycythemia vera, into a second indication, and it hands the drug's maker, PharmaEssentia, a new growth engine at a moment when the rare-disease market has become one of the most competitive corners of the pharmaceutical industry.

The approval matters for the roughly 90,000 people in the United States living with essential thrombocythemia, who face elevated risks of blood clots, stroke and progression to more serious bone marrow disorders. It matters even more for the field of myeloproliferative neoplasms, the family of blood cancers that includes ET, because it represents the first genuinely new treatment option in a generation and because it validates a strategy, repositioning an improved version of a decades-old drug class, that other companies are now watching closely.

Key Facts

BioPharm International reported on Aug 31 that the FDA approved BESREMi for adults with essential thrombocythemia, with Fierce Pharma's coverage the same day noting that the approval marks the first new ET treatment in roughly three decades. The decision was backed by the global Phase 3 SURPASS-ET trial, registered as NCT04285086, which enrolled 174 patients, a modest size that reflects both the rarity of the disease and the difficulty of running trials in a condition where patients can remain stable for years on existing therapy.

The efficacy data hinge on a single striking comparison. CancerNetwork, which covered the approval on Aug 31, noted that in the SURPASS-ET trial, 43% of patients treated with BESREMi achieved a durable modified European LeukemiaNet response, a composite measure of platelet control and related markers, compared with just 6% of patients treated with anagrelide, the drug that has long been a standard option for platelet reduction. The trial also showed fewer thromboembolic events, the blood clots that are the disease's most dangerous complication, over a 12-month period in the BESREMi arm, which is the kind of outcome that matters directly to patients who live in fear of a stroke.

BESREMi is not a new molecule in the way a novel biologic is. Ropeginterferon alfa-2b is a long-acting, pegylated formulation of interferon, a class of immune-system proteins that has been used to treat blood cancers and hepatitis for decades, engineered with a single, well-defined pegylation that extends its half-life and improves tolerability relative to older interferons. The drug has been approved in the United States for polycythemia vera since November 2021, and it already carries approvals for essential thrombocythemia in Japan and Taiwan, meaning the U.S. decision brings a major market into line with the drug's global footprint.

Analysis

The bigger picture here is that BESREMi's approval is a triumph of the repositioning strategy that has quietly become one of the most reliable paths to a new treatment in rare diseases: take a drug with a proven mechanism, reformulate it to fix the tolerability problems that kept it from wide use, and win approval in adjacent indications. What this really means is that PharmaEssentia has essentially turned an old molecule into a new franchise, and the ET approval is the second major payoff of that strategy after polycythemia vera. The clinical logic is sound, because ET and polycythemia vera are closely related myeloproliferative neoplasms with overlapping biology, but the commercial logic is even stronger: a single manufacturing line and a single sales force can now serve two substantial patient populations with the same product.

Fierce Pharma reported on Aug 31 that the approval marks the first new essential thrombocythemia treatment in roughly three decades.

The 43% versus 6% response-rate gap deserves careful reading, because it is both the drug's strongest selling point and its most scrutinized number. On its face, it suggests BESREMi is dramatically more effective than anagrelide, but the comparison has limits. The durable response measure used in the trial is a composite that weights disease-modifying effects, and anagrelide's modest rate reflects the fact that it is a purely palliative platelet-lowering agent rather than a disease modifier. The clinically meaningful interpretation is that BESREMi offers something anagrelide never could: durable control that may alter the underlying disease course, not just manage the platelet count day to day. The reduced thromboembolic events over 12 months reinforce that interpretation, since clot prevention is the outcome that determines whether patients with ET actually live longer, healthier lives.

The competitive implications for the myeloproliferative neoplasm market are significant. PharmaEssentia now holds FDA-approved treatments for both major MPNs, and it is positioned to expand BESREMi's reach while rivals such as Incyte, which has built a franchise around the JAK inhibitor ruxolitinib for myelofibrosis, focus on later-stage disease. For patients, the approval expands the treatment landscape beyond hydroxyurea and anagrelide, the two workhorses that have dominated ET care, and it gives physicians a disease-modifying option that has been shown to produce durable remissions in a meaningful share of patients. The main barriers are practical: the drug is given by injection, unlike the oral agents that patients have grown used to, and its pricing and reimbursement will determine how widely it is actually used.

Why It Matters

For the tens of thousands of Americans with essential thrombocythemia, the approval ends a long therapeutic drought and offers a treatment that aims to modify the disease rather than merely suppress its symptoms, with data showing durable platelet control and fewer clots. For PharmaEssentia, it turns a single-product company into a two-indication franchise and provides a platform for expansion into other countries and potentially other MPN subtypes. For the broader rare-disease field, it demonstrates that a well-executed reformulation of an old drug can win approval and compete with entrenched standards, a lesson with commercial implications for dozens of other molecules whose intolerable early versions kept them off the market. And for oncologists who treat MPNs, it changes the conversation with newly diagnosed patients from a choice among palliatives to a genuine option for disease modification.

CancerNetwork reported on Aug 31 that 43% of BESREMi patients achieved a durable response versus 6% for anagrelide in the SURPASS-ET trial.

The tolerability profile of BESREMi, which the trial data and the drug's real-world use in polycythemia vera support, is central to its clinical case. Older interferons were effective but punishing, with flu-like symptoms, fatigue and depression that drove many patients to abandon treatment, which is one reason they were relegated to second-line use. Ropeginterferon's design, a single pegylation that slows clearance and allows less frequent dosing, was engineered specifically to improve that experience, and the SURPASS-ET results suggest it preserves efficacy while being better tolerated. For a chronic disease where patients may take medication for decades, tolerability is not a soft endpoint, it is the difference between a treatment patients stay on and one they abandon, and it is the reason physicians are likely to consider BESREMi for patients who have failed or cannot tolerate anagrelide and hydroxyurea rather than only as a last resort.

Next Up

In the coming weeks, watch for the drug's pricing and the FDA's required post-marketing studies, which will shape its adoption, and for how quickly it displaces anagrelide and hydroxyurea in real-world prescribing patterns. The longer-term question is whether PharmaEssentia pursues additional indications, since the same pegylated interferon platform has been studied in related conditions, and whether other companies accelerate their own reformulation programs in hematology after seeing BESREMi's success. For patients, the near-term milestone is insurance coverage and access, since a new injection-based therapy for a chronic disease only helps if the health system actually pays for it.

BioPharm International reported on Aug 31 that the drug has been approved in the United States for polycythemia vera since November 2021.